OrthoTrophix announced results of the first proof of principle study of TPX-100 in subjects with bilateral knee osteoarthritis, showing improvements at 6 and 12 months in key knee-related outcome measures.
TPX-100 is an injectable cartilage repair therapeutic agent. Initiated in 2014, the Phase II clinical trial evaluated intra-articular injections of TPX-100 in 115 cases of mild to moderate patello-femoral osteoarthritis involving both knees.
Safety and tolerability of TPX-100 were excellent, and the majority of standardized, patient-reported measures of knee daily function, quality of life and sports/recreation function demonstrated statistically significant and clinically meaningful improvements in the TPX-100-treated knees vs. those receiving placebo.
Sources: OrthoTrophix, Inc.; ORTHOWORLD Inc.
OrthoTrophix announced results of the first proof of principle study of TPX-100 in subjects with bilateral knee osteoarthritis, showing improvements at 6 and 12 months in key knee-related outcome measures.
TPX-100 is an injectable cartilage repair therapeutic agent. Initiated in 2014, the Phase II clinical trial evaluated intra-articular...
OrthoTrophix announced results of the first proof of principle study of TPX-100 in subjects with bilateral knee osteoarthritis, showing improvements at 6 and 12 months in key knee-related outcome measures.
TPX-100 is an injectable cartilage repair therapeutic agent. Initiated in 2014, the Phase II clinical trial evaluated intra-articular injections of TPX-100 in 115 cases of mild to moderate patello-femoral osteoarthritis involving both knees.
Safety and tolerability of TPX-100 were excellent, and the majority of standardized, patient-reported measures of knee daily function, quality of life and sports/recreation function demonstrated statistically significant and clinically meaningful improvements in the TPX-100-treated knees vs. those receiving placebo.
Sources: OrthoTrophix, Inc.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.